Santhera Pharmaceuticals AG (SPHDF) on Tuesday reported a wider full-year loss despite strong revenue growth, driven by higher cost of goods sold linked to milestone expenses and product mix, which offset sales gains.
Operating loss widened to CHF 37.61 million from CHF 33.11 million.
Net loss attributable to shareholders increased to CHF 49.24 million, or CHF 3.78 per share, compared with a loss of CHF 41.97 million, or CHF 3.69 per share in the prior year.
Revenue nearly doubled to CHF 77.19 million from CHF 39.12 million, supported by strong adoption of AGAMREE across Europe and the United States.
Product sales rose to CHF 25.8 million versus CHF 15.0 million previously.
Cash and cash equivalents stood at CHF 22.4 million at year-end, down from CHF 40.9 million at the end of 2024.
Looking ahead, the company expects full-year revenue in the range of CHF 80 million - CHF 90 million and anticipates reaching cash flow break-even in the third quarter of 2026. It reiterated its mid-term target of EUR 150 million in revenue by 2028 and expects to exceed that level by 2030 from its directly operated EU markets.
Separately, Santhera said Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE to treat patients aged four years and older with Duchenne muscular dystrophy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.